Amphion Innovations (AMP)

 

Latest News

Director dealing

RNS Number: 5371B Amphion Innovations PLC 10 January 2018 AMPHION INNOVATIONS PLC ("Amphion" or "the Company") Directors' Dealings London and New York, 10 January 2018 - Amphion Innovations plc (AIM: AMP), the developer of medical, life science, and technology businesses, announces that on 5 January 2018 it granted options over ordinary sh...

Amphion agrees loan restructuring

Amphion Innovations has agreed terms for re-structuring the loan payments and the draw-down of an additional US $1,55...

Comment on Polarean Fund Raise

RNS Number: 1520A Amphion Innovations PLC 22 December 2017 Amphion Innovations plc ("Amphion" or "the Company") Amphion Partner Company, Polarean Imaging Limited, Closes Interim Funding London and New York, 22 December 2017 - Amphion Innovations plc (AIM: AMP), the developer of medical, life science, and technology businesses, announces...

Restructure of Loan and Additional Drawdown

RNS Number: 1523A Amphion Innovations PLC 22 December 2017 AMPHION INNOVATIONS PLC ("Amphion" or "the Company") Extended Repayment and Additional Draw Down on Loan Facility London and New York, Amphion Innovations plc (AIM: AMP), the developer of medical, life science, and technology businesses, announces that the Company has a...

All News

DateHeadlineSource
10-01-18Director dealingRNS
22-12-17Amphion agrees loan restructuringStockMarketWire
22-12-17Comment on Polarean Fund RaiseRNS
22-12-17Restructure of Loan and Additional DrawdownRNS
05-12-17Issue of SharesRNS
01-12-17These five AIM firms could own the tech stars of tomorrowInteractive Investor
23-11-17Amphion update on Polarean's proposed IPOStockMarketWire
23-11-17Further Update on Polarean Imaging LimitedRNS
10-11-17Amphion update on Polarean Imaging StockMarketWire
10-11-17Update on Polarean Imaging LimitedRNS
02-11-17DataTern case against MicroStrategy dismissed StockMarketWire
02-11-17Order Dismissing DataTern CaseRNS
11-10-17Related Party TransactionRNS
05-10-17Amphion partner releases positive clinical resultsStockMarketWire
05-10-17Partner Company releases positive clinical resultsRNS
29-09-17Amphion revenues rise StockMarketWire
29-09-17Half-year ReportRNS
25-09-17Holding(s) in CompanyRNS
25-09-17Sale of Partner Company SharesRNS
30-08-17Amphion reduces stake in Motif BioStockMarketWire
30-08-17Holding(s) in CompanyRNS
30-08-17Sale of partner company sharesRNS
01-08-17AGM StatementRNS
28-06-17FTSE falls on mixed bag led by utilities, oil majorsStockMarketWire
28-06-17Final ResultsRNS
31-05-17Amphion partner company agrees merger StockMarketWire
31-05-17Partner Company m2m Imaging merger updateRNS
23-05-17Amphion draws down additional $1.5mStockMarketWire
22-05-17Additional Draw Down on Loan FacilityRNS
07-02-17Amphion draws down additional $500,000StockMarketWire
07-02-17Additional Draw Down on Loan FacilityRNS
01-02-17Holding(s) in CompanyRNS
30-12-16Holding(s) in CompanyRNS
16-12-16Director/PDMR ShareholdingRNS
09-12-16Director/PDMR ShareholdingRNS
24-11-16Holding(s) in CompanyRNS
08-09-16Amphion re-negotiates terms of Motif CPNStockMarketWire
08-09-16Re-negotiated terms of Motif CPNRNS
07-09-16Amphion NAV up StockMarketWire
07-09-16Interim Results for the six months to 30 June 2016RNS

RSS feeds

  • Editorial news feed for LSE:AMP Editorial
  • Regulatory news feed for LSE:AMP Regulatory

Join interactive investor

  • £22.50 fixed quarterly charge includes £22.50 in trading credits
  • £10 per trade or £6 for frequent traders
  • No % platform fees
  • £1 per trade for regular investment or dividend reinvestment

Open an account